cancer researchOrakl raises $34M to scale AI platform predicting cancer drug responsesParis-based Orakl Oncology has raised an oversubscribed $34 million (€31 million) Series A, co-led by Swedish investor Norrsken VC and French venture firm Singular, to expand its platform combining … more ➔
fundraisingAddex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2Neurosterix, a spinout of Swiss biotech Addex Therapeutics, has raised $105 million (about €94 million) to advance its lead schizophrenia drug into Phase 2 clinical development. The Boston- and Geneva-based … more ➔
small moleculeLakefront abandons Galapagos-developed TYK2 inhibitor after unsuccessful partnering effortsBelgian biotech Lakefront Biotherapeutics, formerly Galapagos, has discontinued its oral TYK2 inhibitor GLPG3667 after analyzing the drug’s competitive landscape and holding talks with potential partners. … more ➔
fundraisingVectorY secures €74.5M to advance ALS gene therapy trialAmsterdam-based VectorY Therapeutics has secured €74.5 million ($83.5 million) in new financing to advance its lead gene therapy candidate for amyotrophic lateral sclerosis (ALS) and expand its pipeline … more ➔
startupSRTD raises €31.5M seed round to develop cell-selective RNA therapiesGermany-based biotech company SRTD Biotech has closed a €31.5 million seed funding round. At the heart of its approach is an RNA technology designed to address a fundamental challenge facing many RNA-based … more ➔
Venture CapitalSwiss VC Redalpine closes eighth fund at $250 millionSwiss venture capital investor Redalpine has closed its eighth fund at $250 million. Redalpine Capital VIII reached its hard cap and was oversubscribed, according to the firm. Less than 12 months passed … more ➔
anti-obesityBoehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remainGerman drugmaker Boehringer Ingelheim and Denmark’s Zealand Pharma have reported positive Phase 3 results for their experimental obesity drug survodutide, which met its primary cardiovascular safety … more ➔
fundraisingOyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinicLondon-based Kesmalea Therapeutics has raised $60 million (about €53.5 million) in a Series A-2 financing and rebranded as Oyster Therapeutics. The funding will support the development of an oral, … more ➔
heart diseaseNovo, Novartis drugs cut heart-risk markers but not cardiovascular eventsDanish drugmaker Novo Nordisk’s anti-inflammatory antibody ziltivekimab and Swiss drugmaker Novartis’ lipoprotein(a)-lowering drug pelacarsen sharply reduced their targeted blood markers but failed to … more ➔
Meanwhile in biotechWindward targets $204M IPO; Valneva’s Shigella vaccine meets Phase 2 endpoint; Ethris’ nasal mRNA lowers viral loadA Swiss biotech moves closer to Nasdaq, while Valneva and Ethris report mid-stage clinical results. This week’s roundup also covers a takeover offer for Egetis, Sanofi’s latest pipeline cut and Vivoryon’s … more ➔
